)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Korro Bio (KRRO) investor relations material
Korro Bio Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary12 Aug, 2025
Executive summary
Clinical-stage biopharma focused on RNA editing therapies, with lead candidate KRRO-110 in Phase 1/2a for AATD and a pipeline targeting additional indications.
Over 80% of planned healthy volunteers dosed in KRRO-110 trial; no serious adverse events or dose-limiting toxicities observed as of August 12, 2025.
KRRO-110 received orphan drug designation from both FDA and EMA in 2025.
Collaboration with Novo Nordisk progressing, targeting cardiometabolic diseases.
Announced a 19% workforce reduction in May 2025 as part of operational streamlining.
Financial highlights
Cash, cash equivalents, and marketable securities totaled $119.6M as of June 30, 2025, down from $163.1M at December 31, 2024.
Collaboration revenue of $4.0M for the six months ended June 30, 2025, including $1.5M in Q2 2025 from Novo Nordisk; no product sales revenue.
Net loss of $49.2M for the six months ended June 30, 2025, and $25.8M for Q2 2025.
R&D expenses rose to $40.8M for H1 2025 and $21.0M for Q2 2025, mainly due to increased clinical trial activity and personnel costs.
G&A expenses were $15.5M for H1 2025 and $7.6M for Q2 2025, up year-over-year.
Outlook and guidance
Cash runway expected to fund operations and capital expenditures into 2027, including completion of the KRRO-110 Phase 1/2a trial.
Interim data from the KRRO-110 trial expected in H2 2025; full trial completion anticipated in 2026.
Plans to announce a development candidate for the rare metabolic disorder program by year-end 2025.
Ongoing evaluation of additional funding options, including equity, debt, and collaborations.
When is the REWRITE trial completion expected?
Discuss the goal of the 3-2-1 strategy.
Detail the terms of the Novo Nordisk collaboration.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Korro Bio earnings date
Q3 202512 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Korro Bio Inc. is a biopharmaceutical company engaged in the field of RNA editing to develop new genetic medicines. The company's innovative approach, leveraging the Oligonucleotide Promoted Editing of RNA (OPERA) platform, aims to harness natural processes for making transient, reversible changes to genetic instructions. This technology seeks to offer potential treatments for patients with rare and highly prevalent diseases by overcoming the complexities of earlier gene-editing methods. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage